NewAmsterdam Pharma (NAMS) Return on Sales (2023 - 2026)

NewAmsterdam Pharma (NAMS) has 4 years of Return on Sales data on file, last reported at 0.16% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales fell 3.0% year-over-year to 0.16%; the trailing twelve-month figure through Mar 2026 stood at 0.09% (down 5.0% YoY), and the FY2025 full-year result was 0.09%, down 4.0% from the prior year.
• Return on Sales climbed to 0.16% in Q1 2026, from 23.41% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.72% in Q4 2023 to a low of 23.41% in Q4 2025.
• A 4-year average of 2.18% and a median of 0.15% in 2026 frame the typical range for Return on Sales.
• Peak annual rise in Return on Sales reached 54 bps in 2025, while the deepest fall reached 2334 bps in 2025.
• Tracing NAMS's Return on Sales over 4 years: stood at 0.72% in 2023, then plunged by 110 bps to 0.07% in 2024, then tumbled by 32342 bps to 23.41% in 2025, then jumped by 99 bps to 0.16% in 2026.
• Business Quant data shows NAMS's Return on Sales at 0.16% in Q1 2026, 23.41% in Q4 2025, and 2.07% in Q3 2025.